Impromune

Impromune®

YOUR REFERENCE PRODUCT FOR THE IMMUNE SYSTEM (1)
What is it? What is it for?
Datasheet

Composition

Each palatable tablet contains:

Nucleoforce® (Yeast extract S. cerevisiae

with Nucleotides)

585mg

AHCC (Lentinus edodes, mushroom)

315 mg

Magnesium stearate

 

 

Storage conditions

Keep in a cool, dry place.

Dosage and form of administration

Administering IMPROMUNE® is easy thanks to its great palatability. Due to its design, the tablets can be divided to make it easier for smaller animals to swallow them. Depending on the case and the animal’s progression, the administration period can be lengthened according to the veterinarian's instructions.

Animal weight Daily tablets
<10 kg 1/2
11-25 kg 1
>26 kg 2

 

IMPROMUNE® does not cause adverse effects.

Recommended use (3,4,5):

 

Use of IMPROMUNE®

Infectious processes:

• Bacteria (e.g. pyogenic infection), viruses (e.g. calicivirus, papillomatosis), Parasites (e.g.: demodicosis, giardia), fungal infections (e.g.: ringworm, Malassezia)

• Leishmania

 

 

Minimum duration 15-20 days

 

 

Minimum duration 6 months

 

Acquired immunosuppression:

• Administration of immunosuppressants (e.g. glucocorticoids)

• Chemotherapy

• Elderly animals, immunosenescence

• Stress:

Postoperative/post-multiple trauma conditions (e.g. Caesarean section, pyometra)

Reproduction (e.g. lactation, large litters) Puppies (e.g.: around vaccine period)

Malnutrition

 

Before and after treatment, 15-20 days

Before, during and after chemotherapy, 15-20 days

Minimum duration 30 days

 

 

Minimum duration 30 days

Minimum duration 30 days

Minimum duration 30 days

Presentation

In containers of 20 or 40 tablets, pouches of 200 tablets.

Each clinical package contains: 20 blister packs of 10 tablets or 12 dispenser sachets.

 

References:

3, Romano V, Martínez-Puig D, Torre C, Iraculis N, Vilaseca LI, Chetrit C, Journal of Animal Physiology and Animal Nutrition Journal compilation, 2007.
4, Segarra S, Miró G, Montoya A, et al. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis, Vet Parasitol, 2017;239:50-56.
5, Segarra S, Miró G, Montoya A, Pardo-Marín L, Teichenné J, Ferrer L, Cerón JJ, Prevention of disease progression in Leishmania infantum-infected dogs with dietary nucleotides and active hexose correlated compound, Parasit
Vectors. 2018 Feb 21;11(1):103.